Hypoxia signaling: Challenges and opportunities for cancer therapy

被引：31

作者：

Ivan, Mircea ^{[1
,2
]}

Fishel, Melissa L. ^{[3
,4
]}

Tudoran, Oana M. ^{[5
]}

Pollok, Karen E. ^{[3
]}

Wu, Xue ^{[6
]}

Smith, Paul J. ^{[7
]}

机构：

[1] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA

[2] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN USA

[3] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN USA

[4] IU Simon Comprehens Canc Ctr, Dept Pharmacol & Toxicol, Indianapolis, IN USA

[5] Oncol Inst Prof Dr Ion Chiricuta, Cluj Napoca, Cluj, Romania

[6] Ohio State Univ, Columbus, OH USA

[7] Cardiff Univ, Sch Med, Cardiff, Wales

来源：

SEMINARS IN CANCER BIOLOGY | 2022年 / 85卷

关键词：

Hypoxia; HIF1; HIF2; HIF inhibitors; Hypoxia-activated prodrug; SMALL-MOLECULE INHIBITOR; ANTI-ANGIOGENIC THERAPY; DNA TOPOISOMERASE-II; CYTOCHROMES P450 CYP; RENAL-CELL CARCINOMA; INDUCIBLE FACTOR; ACTIVATED PRODRUG; N-OXIDE; HEPATOCELLULAR-CARCINOMA; PROLYL HYDROXYLASE;

D O I：

10.1016/j.semcancer.2021.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hypoxia is arguably the first recognized cancer microenvironment hallmark and affects virtually all cellular populations present in tumors. During the past decades the complex adaptive cellular responses to oxygen deprivation have been largely elucidated, raising hope for new anti cancer agents. Despite undeniable preclinical progress, therapeutic targeting of tumor hypoxia is yet to transition from bench to bedside. This review focuses on new pharmacological agents that exploit tumor hypoxia or interfere with hypoxia signaling and discusses strategies to maximize their therapeutic impact.

引用

页码：185 / 195

页数：11

共 50 条

[31] Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Baran, Natalia
Konopleva, Marina
CLINICAL CANCER RESEARCH, 2017, 23 (10) : 2382 - 2390
[32] Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy
Rey, Sergio
Schito, Luana
Wouters, Bradly G.
Eliasof, Scott
Kerbel, Robert S.
TRENDS IN CANCER, 2017, 3 (07): : 529 - 541
[33] Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
Li, Yue
Zhao, Long
Li, Xiao-Feng
FRONTIERS IN ONCOLOGY, 2021, 11
[34] Nitric oxide signaling in hypoxia
Ho, J. J. David
Man, H. S. Jeffrey
Marsden, Philip A.
JOURNAL OF MOLECULAR MEDICINE-JMM, 2012, 90 (03): : 217 - 231
[35] Cancer therapy that targets the Hedgehog signaling pathway considering the cancer microenvironment
Onishi, Hideya
Nakamura, Katsuya
Yanai, Kosuke
Nagai, Shuntaro
Nakayama, Kazunori
Oyama, Yasuhiro
Fujimura, Akiko
Ozono, Keigo
Yamasaki, Akio
ONCOLOGY REPORTS, 2022, 47 (05)
[36] Detection of Hypoxia in Cancer Models: Significance, Challenges, and Advances
Godet, Ines
Doctorman, Steven
Wu, Fan
Gilkes, Daniele M.
CELLS, 2022, 11 (04)
[37] Targeting Pim kinases for cancer treatment: opportunities and challenges
Le, Bich Thuy
Kumarasiri, Malika
Adams, Julian R. J.
Yu, Mingfeng
Milne, Robert
Sykes, Matthew J.
Wang, Shudong
FUTURE MEDICINAL CHEMISTRY, 2015, 7 (01) : 35 - 53
[38] Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukurnura, Dal
Kloepper, Jonas
Amoozgar, Zohreh
Duda, Dan G.
Jain, Rakesh K.
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (05) : 325 - 340
[39] Vaccines for cancer prevention: exploring opportunities and navigating challenges
Graciotti, Michele
Kandalaft, Lana E.
NATURE REVIEWS DRUG DISCOVERY, 2025, 24 (02) : 134 - 150
[40] Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories
Gonzalez, Alvaro
Lopez-Borrego, Silvia
Sandua, Amaia
Vales-Gomez, Mar
Alegre, Estibaliz
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2024, 61 (06) : 435 - 457

← 1 2 3 4 5 →